Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by TriSalus Life Sciences

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces the Launch of the TriNav FLX Infusion System
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Reports First Quarter 2025 Results and Provides Updated 2025 Guidance
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences to Host First Quarter 2025 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences® Announces That Its Researchers Received Two JVIR Top Paper Awards for the Publication of “Intra-arterial Pressure-Enabled Drug Delivery™ Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model”
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Key Appointments to Board of Directors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Drawdown of $10 Million Tranche Under Credit Agreement with OrbiMed
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences® Announces Publication of Pre-Clinical Data Demonstrating Improved Delivery of Embospheres® to Liver Tumors using Pressure-Enabled Drug Delivery™ (PEDD™) via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Announces Leadership Changes
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Reports Q3 2024 Financial Results and Provides Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Reports Q2 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Reports Q1 2024 Financial Results and Business Update
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
From TriSalus Life Sciences
Via Business Wire
Tickers TLSI
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.